Cornerstone Capital Management Holdings’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-26,726	Closed	-$2.2M	–	1390
2016 Q1	$2.2M	Sell	26,726 -3,812	-12%	-$310K	0.02%	697
2015 Q4	$3.2M	Sell	30,538 -4,620	-13%	-$482K	0.03%	591
2015 Q3	$3.7M	Buy	35,158 +32,538	+1,242%	+$4.35M	0.03%	520
2015 Q2	$358K	Buy	+2,620	New	+$325K	﹤0.01%	1078
2013 Q4	–	Sell	-1,047	Closed	-$75K	–	1258
2013 Q3	$75K	Sell	1,047 -17,469	-94%	-$1.16M	﹤0.01%	1145
2013 Q2	$1.03M	Buy	+18,516	New	+$1.15M	0.01%	797

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cornerstone Capital Management Holdings's BMRN Position: Q2 2016 in Review

Cornerstone Capital Management Holdings sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2016, closing a stake of 26,726 shares — an estimated $2.2M sold.

Cornerstone Capital Management Holdings first reported a position in BMRN in Q2 2013 and held it in 6 quarters. The position peaked at $3.7M in Q3 2015. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2016.

Cornerstone Capital Management Holdings reported no remaining BioMarin Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Cornerstone Capital Management Holdings sold 26,726 BioMarin Pharmaceuticals shares in Q2 2016, an estimated $2.2M.
Cornerstone Capital Management Holdings first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Cornerstone Capital Management Holdings's BioMarin Pharmaceuticals position peaked at $3.7M in Q3 2015.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2016.

Based on Cornerstone Capital Management Holdings's 13F filing for Q2 2016, filed 12 Aug 2016.